Mineralys Therapeutics (MLYS) Expected to Announce Earnings on Thursday

Mineralys Therapeutics (NASDAQ:MLYS) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Mineralys Therapeutics to post earnings of ($1.02) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Stock Up 1.4 %

Shares of Mineralys Therapeutics stock opened at $15.63 on Tuesday. Mineralys Therapeutics has a 52-week low of $8.24 and a 52-week high of $18.38. The company has a 50 day moving average of $13.55 and a 200 day moving average of $12.38. The company has a market capitalization of $1.01 billion, a P/E ratio of -4.29 and a beta of -0.30.

Analyst Ratings Changes

Several research firms recently commented on MLYS. The Goldman Sachs Group dropped their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, HC Wainwright boosted their target price on Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, April 2nd.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total transaction of $129,729.42. Following the transaction, the chief financial officer now owns 215,340 shares of the company’s stock, valued at $2,597,000.40. The trade was a 4.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider David Malcom Rodman sold 11,366 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $14.53, for a total value of $165,147.98. Following the completion of the sale, the insider now directly owns 111,686 shares of the company’s stock, valued at $1,622,797.58. The trade was a 9.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,213 shares of company stock worth $1,360,567. Corporate insiders own 33.24% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.